These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9142433)

  • 21. [Acute hemodynamic effects of pimobendan and captopril: a comparative study in the same patients with chronic heart failure].
    Tsuda T; Izumi T; Kodama M; Hanawa H; Ohshima M; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Shibata A
    J Cardiol; 1992; 22(4):721-9. PubMed ID: 1343639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy.
    Permanetter B; Sebening H; Hartmann F; Baumann G; Lutilsky L
    J Cardiovasc Pharmacol; 1989 Dec; 14(6):803-9. PubMed ID: 2481765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure.
    Ishiki R; Ishihara T; Izawa H; Nagata K; Hirai M; Yokota M
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):897-905. PubMed ID: 10836724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
    Satoh K; Satoh Y; Imagawa J; Taira N
    Jpn Heart J; 1993 Mar; 34(2):213-9. PubMed ID: 8315818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic profile of the cardiotonic agent pimobendan.
    van Meel JC; Diederen W
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D; Fry D
    Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
    Baumann G; Ningel K; Permanetter B
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    Rector TS; Cohn JN
    Am Heart J; 1992 Oct; 124(4):1017-25. PubMed ID: 1529875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    Hagemeijer F
    Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR; Minors SL; O'Sullivan ML; Horne R
    J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
    J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy.
    Fuentes VL; Corcoran B; French A; Schober KE; Kleemann R; Justus C
    J Vet Intern Med; 2002; 16(3):255-61. PubMed ID: 12041654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the pharmacology and clinical uses of pimobendan.
    Boyle KL; Leech E
    J Vet Emerg Crit Care (San Antonio); 2012 Aug; 22(4):398-408. PubMed ID: 22928748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute and chronic effects of UDCG 115 BS (pimobendan) in patients with advanced myocardial failure].
    Permanetter B; Baumann G; Wirtzfeld A; Günes S; Stinshoff M; Klein G
    Z Kardiol; 1989 May; 78(5):335-42. PubMed ID: 2660451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.